Jakub Pysiewicz

Jakub Pysiewicz

Auto-generated profile, based on publicly available information

Jakub Pysiewicz

Provincial Hospital in Zgierz, Parzęczewska 35, 95-100 Zgierz, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MBMichał Bereza
Michał Bereza
MDMateusz Dembiński
Mateusz Dembiński
KKKacper Kmieć
Kacper Kmieć
APAnna Maria Pietrzak
Anna Maria Pietrzak
JPJulia Prabucka-Marciniak
Julia Prabucka-Marciniak
KZKamila Zych
Kamila Zych
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematopoietic stem cell disorder driven by somatic PIGA mutations, leading to uncontrolled complement activation, intravascular hemolysis, and thrombotic risk. Pediatric PNH represents fewer than 10% of cases and demonstrates a distinct clinical phenotype that complicates diagnosis and management. Methods: A comprehensive literature search of PubMed, Embase, Web of Science, and Scopus was conducted through July 2025 using predefined keywords related to PNH, pediatrics, bone marrow failure, and complement inhibitors. Eligible studies included clinical trials, registry data, systematic reviews, case series, and case reports. Relevant adult studies were also reviewed when mechanistic or therapeutic insights were applicable to pediatric disease. Data were synthesized narratively, focusing on pathophysiology, clinical spectrum, diagnostic approaches, and therapeutic advances. Results: Pediatric PNH most often presents with bone marrow failure syndromes rather than classic hemolytic features. Hemoglobinuria is infrequent, while cytopenias predominate. Thrombosis, though less common than in adults, remains a serious complication. High-sensitivity flow cytometry enables early and accurate diagnosis, particularly for small clone sizes. Complement inhibitors—including eculizumab, ravulizumab, and crovalimab—have markedly improved survival and reduced morbidity, while emerging agents targeting proximal complement pathways (pegcetacoplan, iptacopan, danicopan) show promise. Hematopoietic cell transplantation remains the only curative option but is reserved for selected patients. Conclusions: Pediatric PNH differs significantly from adult disease in presentation and management. Advances in complement inhibition have transformed prognosis, but further pediatric-specific research and inclusion in clinical trials are urgently needed to establish evidence-based guidelines and optimize long-term outcomes.

4 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MBMichał Bereza
Michał Bereza
KKKacper Kmieć
Kacper Kmieć
ESEdyta Szymańska
Edyta Szymańska
MDMateusz Dembiński
Mateusz Dembiński
JPJulia Prabucka-Marciniak
Julia Prabucka-Marciniak
MRMarlena Rycyk
Marlena Rycyk
Background: Precision medicine, driven by advances in genomics, is reshaping the approach to diagnosis, risk assessment, and treatment planning in cardiac surgery. By analyzing genetic variation and molecular pathways, clinicians can move beyond standardized protocols toward individualized surgical care. Methods: This review synthesizes recent literature on the integration of genomic technologies - such as whole genome sequencing, gene expression profiling, and pharmacogenomics - into the preoperative, intraoperative, and postoperative phases of cardiac surgery. Sources include peer-reviewed articles, clinical trial data, and translational research reports published over the past 20 years. Results: Genomic profiling enables improved risk stratification, early detection of hereditary cardiovascular diseases, and identification of genetic biomarkers predictive of surgical outcomes. Pharmacogenomic insights allow optimization of perioperative drug therapy, reducing complications and enhancing recovery. Emerging applications include bioinformatics-driven surgical planning and integration of multi-omic data for real-time decision support. However, challenges remain regarding data interpretation, ethical considerations, and integration into clinical workflows. Conclusion: Precision medicine and genomics hold significant promise for improving patient-specific outcomes in cardiac surgery. Their successful implementation will require robust clinical evidence, interdisciplinary collaboration, and infrastructure to manage and interpret complex genomic data. Ongoing research is likely to expand their role from risk prediction to fully individualized surgical strategies.

25 August 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MBMichał Bereza
Michał Bereza
MDMateusz Dembiński
Mateusz Dembiński
JPJulia Prabucka-Marciniak
Julia Prabucka-Marciniak
ESEdyta Szymańska
Edyta Szymańska
JKJoanna Kaszczewska
Joanna Kaszczewska
KKKacper Kmieć
Kacper Kmieć
Pediatric patients undergoing cardiac surgery, particularly with cardiopulmonary bypass (CPB), are at high risk for significant bleeding and allogeneic blood transfusions due to their unique hemostatic profile. Tranexamic acid (TXA) is the primary antifibrinolytic agent used to mitigate this risk, but its efficacy, safety, and optimal administration in this population remain topics of debate. This article provides a comprehensive review and to synthesize the available evidence and identify critical knowledge gaps. Our analysis confirms that TXA significantly reduces postoperative blood loss and the need for allogeneic red blood cell and fresh frozen plasma transfusions. This effect was particularly notable in high-risk subgroups such as infants and cyanotic patients. Substantial heterogeneity was found across studies, primarily related to varying TXA dosing regimens and differing transfusion protocols, which limited the ability to define a single optimal dose. TXA is an effective agent for reducing bleeding and transfusion needs in pediatric cardiac surgery, but its use is associated with a potential, dose-dependent risk of seizures. The wide variability in dosing regimens and the lack of robust data on long-term neurological outcomes highlight a critical need for future large-scale, prospective trials. These studies should aim to standardize dosing protocols and definitively assess the true benefit-to-risk ratio of TXA in specific pediatric subgroups.

3 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MDMateusz Dembiński
Mateusz Dembiński
MBMichał Bereza
Michał Bereza
JPJulia Prabucka-Marciniak
Julia Prabucka-Marciniak
ESEdyta Szymańska
Edyta Szymańska
JPJakub Pysiewicz
Jakub Pysiewicz
HRHubert Rycyk
Hubert Rycyk
Vascular diseases are a major source of global morbidity and mortality, often requiring surgical intervention, but the long-term outcomes are frequently compromised by complications like graft failure and restenosis. Since traditional imaging methods often detect these issues only at an advanced stage, there is a critical need for more precise and earlier risk prediction tools. This comprehensive narrative review synthesizes existing literature on the predictive value of circulating and tissue-based biomarkers for these adverse outcomes. The study systematically examined major electronic databases including PubMed, Scopus, and Web of Science, utilizing keywords related to vascular surgery, outcomes (e.g., graft failure, restenosis), and biomarkers. The identified biomarkers were categorized into four principal groups: inflammatory, lipid-related, genetic, and novel/emerging markers. The review found that elevated levels of inflammatory markers—such as high-sensitivity C-reactive protein (hs-CRP) and various interleukins (IL-6, IL-1β, TNF-α, IL-18, IL-33)—are strongly associated with an increased risk of graft failure and restenosis. Conversely, anti-inflammatory interleukins like IL-10 and IL-19 were found to correlate with a reduced risk. Furthermore, an unfavorable lipid profile (high LDL, low HDL, or an elevated LDL/HDL ratio) was consistently linked to a higher incidence of these complications. The review also highlights the promising potential of genetic markers, such as specific single nucleotide polymorphisms (SNPs), and novel biomarkers like non-coding RNAs in developing personalized treatment strategies. The findings suggest that incorporating biomarker panels into routine clinical practice could significantly enhance preoperative risk stratification, enabling tailored perioperative therapy and more effective postoperative surveillance. By allowing for the early detection of biological evidence of graft compromise, this precision-medicine model has the potential to substantially improve long-term patient outcomes in vascular surgery.

16 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JPJulia Prabucka-Marciniak
Julia Prabucka-Marciniak
MBMichał Bereza
Michał Bereza
MDMateusz Dembiński
Mateusz Dembiński
KKKacper Kmieć
Kacper Kmieć
JPJakub Pysiewicz
Jakub Pysiewicz
ESEdyta Szymańska
Edyta Szymańska
Background: Hematopoietic stem cell transplantation (HSCT) has expanded its scope as a curative therapy for a wide range of severe pediatric diseases. However, its efficacy is frequently challenged by graft-versus-host disease (GVHD), a significant and potentially fatal complication. This is particularly relevant in the pediatric population, where unique immunological and physiological factors contribute to a distinct disease course. Objective: This narrative review synthesizes the current evidence base on the treatment and management of GVHD in pediatric patients. It aims to provide a critical appraisal of the unique immunological determinants, current prophylactic and treatment interventions, and the long-term morbidities and clinical needs for this specific field. Methods: A comprehensive systematic search of databases, including PubMed, Embase, and the Cochrane Library, was conducted to identify relevant literature. Articles were selected based on inclusion criteria focusing on GVHD management in patients aged 18 or younger, while excluding non-peer-reviewed articles and case reports. Data on study design, patient populations, treatment regimens, and key outcomes were extracted and synthesized. Summary: The pathogenesis of acute GVHD (aGVHD) is described by the classic three-phase model, beginning with host tissue damage, followed by donor T-cell activation, and culminating in targeted organ destruction, particularly in the skin, liver, and gastrointestinal tract. Diagnostic methods have evolved from clinical and histological assessments to include advanced biomarker-driven approaches, such as the MAGIC algorithm, which provides more precise prognostic risk stratification. Current prophylaxis strategies primarily involve calcineurin inhibitors in combination with methotrexate or mycophenolate mofetil. Novel agents like ruxolitinib and vedolizumab are emerging as promising therapeutic tools for both prophylaxis and the treatment of steroid-refractory disease. Despite these advancements, significant clinical gaps persist, as many established guidelines for GVHD management are not tailored to the pediatric population. The evident age-related disparity in GVHD risk highlights the critical need for pediatric-specific research. Conclusion: While substantial progress has been made in understanding and treating GVHD, there is a clear and urgent need for further research focused on pediatric-specific protocols. Continued efforts to validate existing therapies in pediatric cohorts, explore novel agents, and leverage biomarkers are essential to improve outcomes and the quality of life for young patients undergoing HSCT.

17 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KKKacper Kmieć
Kacper Kmieć
ESEdyta Szymańska
Edyta Szymańska
MBMichał Bereza
Michał Bereza
MDMateusz Dembiński
Mateusz Dembiński
JPJulia Prabucka-Marciniak
Julia Prabucka-Marciniak
JPJakub Pysiewicz
Jakub Pysiewicz
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for a variety of pediatric hematologic and non-malignant disorders, yet chronic graft-versus-host disease (cGVHD) remains the primary cause of long-term non-relapse morbidity and mortality. The incidence of cGVHD in children has been increasing, a trend associated with the expanded use of peripheral blood stem cells and unrelated donors. Despite generally lower rates than adults, cGVHD remains a significant and growing clinical problem with profound long-term implications for pediatric survivors, who have a much greater life expectancy. Objective: This review aims to provide a focused and much-needed overview of cGVHD in children. Specifically, it delineates the unique epidemiological, pathobiological, and clinical characteristics that distinguish the disease in this population, including immunological distinctions, diagnostic challenges, and special considerations for long-term effects. This report highlights the pressing questions in treatment and research, addressing the historical lack of specialized data and emphasizing the principle that "children are not small adults" in the context of this complex condition. Methods: This review was conducted by systematically analyzing and synthesizing peer-reviewed articles, clinical guidelines, and consensus statements related to pediatric cGVHD. A comprehensive literature search was performed across databases including PubMed, Scopus, and Embase using a combination of keywords such as "pediatric," "chronic GvHD," "children," "hematopoietic stem cell transplantation," "management," "diagnosis," and "long-term effects." Summary: The lower incidence and severity of cGVHD in children are attributable to distinct biological factors, including superior thymic function and a greater use of bone marrow or cord blood grafts. However, diagnostic challenges persist due to non-specific symptoms and the limitations of adult-derived criteria. The profound and age-specific impacts of the disease and its treatments on growth, neurocognitive development, and infectious risk underscore the disproportionate long-term burden on pediatric survivors. The review discusses therapeutic strategies that prioritize steroid-sparing regimens and the integration of novel targeted inhibitors and cellular therapies. Conclusion: A paradigm shift is necessary, advocating for dedicated pediatric research, age-adapted diagnostic tools, and a multidisciplinary, holistic approach to long-term survivorship care to optimize the functional status and quality of life for children with cGVHD.